AIM: To assesses the safety and efficacy of Aspergillus niger prolyl endoprotease (AN-PEP)
to mitigate the immunogenic effects of gluten in celiac patients. METHODS: Patients with …

BACKGROUND The gluten-free diet (GFD) has limitations, and there is intense research in
the development of adjuvant therapies. AIM To examine the effects of orally administered …

Background Aspergillus niger prolyl endoprotease (AN‐PEP) efficiently degrades gluten
molecules into non‐immunogenic peptides in vitro. Aim To assess the efficacy of AN‐PEP …

The Aspergillus niger-derived prolyl endoprotease (AN-PEP) has previously been shown to
degrade gluten in healthy subjects when added to an intragastrically infused meal. The …

Objective. Enzyme therapy based on animal digestive extracts was investigated as a means
of completely digesting toxic residues from gluten in the small intestine, thus providing a …

Background and Aims Celiac disease (CeD) is an immune-mediated disorder triggered by
the ingestion of gluten. Despite adhering to a gluten-free diet (the only management option …

Methods: We selected patients with NCGS by screening demographic interviews, as well as
performing medical evaluations, anti-gluten antibody tests, and gluten challenge tests. We …

Background: Coeliac disease is caused by an immune response to gluten. As gluten
proteins are proline rich they are resistant to enzymatic digestion in the gastrointestinal tract …

Celiac disease (CD) is caused by intolerance to gluten. Oral supplementation with enzymes
like Aspergillus niger propyl-endoprotease (AN-PEP), which can hydrolyse gluten, has been …

Background: The only treatment for celiac disease (CD) is a gluten-free diet (GFD).
However, there is interest among patients in a medical therapy to replace or help with a …